title: Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow.
abstract: The emerging clinical relevance of bone marrow micrometastasis has prompted several investigations, using a variety of immunocytochemical approaches. The present study was designed to evaluate some of the variables affecting the immunocytochemical detection of individual epithelial tumor cells in bone marrow. Using an alkaline phosphatase-antialkaline phosphatase staining technique, we evaluated bone marrow aspirates from 358 patients with primary carcinomas of the breast (n = 150), lung (n = 66), prostate (n = 42), or colorectum (n = 100). Individual tumor cells in cytological preparations were detected with monoclonal antibody (MAb) CK2 to the epithelial cytokeratin component 18 (CK18), which has been validated in extensive clinical studies. In addition, the utility of the broad-spectrum MAb A45-B/B3 was explored in this study. The high specificity of MAbs CK2 and A45-B/B3 was supported by analysis of bone marrow from 75 noncarcinoma control patients and by double-marker analysis with MAbs to mesenchymal marker proteins (CD45 and vimentin). In contrast, MAbs E29 and HMFG1, directed to mucin-like epithelial membrane proteins, cross-reacted with hematopoietic cells in 26.7-42.7% of all samples tested. The majority of the 154 positive samples (43.0%) from cancer patients displayed less than 10 CK18-positive cells per 8 x 10(5) marrow cells analyzed. The detection rate, however, was affected by blood contamination of the aspirate, the number of aspirates analyzed, and the number of marrow cells screened per aspiration site. Comparative immunostaining of bone marrow specimens with MAbs CK2 and A45-B/B3 indicated that downregulation of CK18 in micrometastatic carcinoma cells occurs in about 50% of the 172 samples analyzed, regardless of the primary tumor origin.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Institut für Immunologie, Ludwig-Maximilians-Universität, München, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Pantel
authors.forename: G
authors.initials: G
authors.lastname: Schlimok
authors.forename: M
authors.initials: M
authors.lastname: Angstwurm
authors.forename: D
authors.initials: D
authors.lastname: Weckermann
authors.forename: W
authors.initials: W
authors.lastname: Schmaus
authors.forename: H
authors.initials: H
authors.lastname: Gath
authors.forename: B
authors.initials: B
authors.lastname: Passlick
authors.forename: J R
authors.initials: JR
authors.lastname: Izbicki
authors.forename: G
authors.initials: G
authors.lastname: Riethmüller
mesh_terms: D000469:Alkaline Phosphatase / Q000032:analysis; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology*; D001943:Breast Neoplasms / Q000473:pathology*; D015179:Colorectal Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D007633:Keratins / Q000032:analysis; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis; D018396:Mucin-1; D009077:Mucins / Q000032:analysis; D009362:Neoplasm Metastasis / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D012680:Sensitivity and Specificity
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D008562:Membrane Glycoproteins; D018396:Mucin-1; D009077:Mucins; D007633:Keratins; D000469:Alkaline Phosphatase